We are live on ! Find out more
NVS icon

Novartis

1,128 hedge funds and large institutions have $20.7B invested in Novartis in 2020 Q2 according to their latest regulatory filings, with 83 funds opening new positions, 408 increasing their positions, 421 reducing their positions, and 78 closing their positions.

New
Increased
Maintained
Reduced
Closed

88% more call options, than puts

Call options by funds: $203M | Put options by funds: $108M

6% more first-time investments, than exits

New positions opened: 83 | Existing positions closed: 78

2% more capital invested

Capital invested by funds: $20.4B → $20.7B (+$333M)

0.08% less ownership

Funds ownership: 9.71%9.63% (-0.08%)

0% less funds holding

Funds holding: 1,1331,128 (-5)

3% less repeat investments, than reductions

Existing positions increased: 408 | Existing positions reduced: 421

50% less funds holding in top 10

Funds holding in top 10: 3015 (-15)

Holders
1,128
Holders Change
-5
Holders Change %
-0.44%
% of All Funds
23.13%
Holding in Top 10
15
Holding in Top 10 Change
-15
Holding in Top 10 Change %
-50%
% of All Funds
0.31%
New
83
Increased
408
Reduced
421
Closed
78
Calls
$203M
Puts
$108M
Net Calls
+$95.1M
Net Calls Change
+$44.4M
Name Holding Trade Value Shares
Change
Change in
Stake
DADC
76
D.A. Davidson & Co
Montana
$28.6M -$4.69M -54,306 -14%
CCM
77
Causeway Capital Management
California
$28.5M -$47.3K -548 -0.2%
TAM
78
Tocqueville Asset Management
New York
$27.9M +$3.23M +37,475 +13%
Brown Advisory
79
Brown Advisory
Maryland
$27.6M -$7.94K -92 -0%
US Bancorp
80
US Bancorp
Minnesota
$27.6M -$475K -5,505 -2%
JMPWA
81
JP Morgan Private Wealth Advisors
California
$26.9M -$227K -2,632 -0.8%
OAM
82
Oppenheimer Asset Management
New York
$26.7M -$653K -7,566 -2%
SC
83
Saturna Capital
Washington
$25.8M +$34.5K +400 +0.1%
EVM
84
Eaton Vance Management
Massachusetts
$24.6M -$300K -3,470 -1%
OCM
85
Osterweis Capital Management
California
$23.9M -$1.5M -17,325 -6%
CCMG
86
Clark Capital Management Group
Pennsylvania
$23.4M +$23.1M +267,968 New
T. Rowe Price Associates
87
T. Rowe Price Associates
Maryland
$23.3M -$11.3M -130,456 -33%
GG
88
Gofen & Glossberg
Illinois
$22.2M
CIM
89
Confluence Investment Management
Missouri
$22.1M +$231K +2,680 +1%
Janney Montgomery Scott
90
Janney Montgomery Scott
Pennsylvania
$21.4M -$808K -9,365 -4%
OA
91
Oak Associates
Ohio
$21.2M -$271K -3,141 -1%
M&T Bank
92
M&T Bank
New York
$20.9M +$367K +4,247 +2%
BCWM
93
Bartlett & Co Wealth Management
Ohio
$20.5M -$267K -3,092 -1%
BC
94
Bartlett & Co
Ohio
$20.5M -$267K -3,092 -1%
RJFSA
95
Raymond James Financial Services Advisors
Florida
$20.4M -$168K -1,950 -0.8%
NA
96
NewEdge Advisors
Louisiana
$19.9M +$2.86M +33,141 +17%
FCI
97
Financial Counselors Inc
Kansas
$19.8M +$1.64M +19,016 +9%
EWA
98
Exencial Wealth Advisors
Oklahoma
$19.4M +$350K +4,057 +2%
LPL Financial
99
LPL Financial
California
$19.2M +$1.11M +12,878 +6%
Citigroup
100
Citigroup
New York
$19.2M -$2.62M -30,405 -12%

NVS Hedge Fund Activity: Q2 2020 in Review

1,128 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q2 2020, worth a combined $20.7B — up 1.6% from $20.4B a quarter earlier.

Buyers outnumbered sellers: 83 funds opened new NVS positions and 78 closed out — a net gain of 5 holders — while 408 added to existing stakes and 421 trimmed.

The largest buyer was Boston Partners, adding an estimated $290M. The largest seller was Dodge & Cox, cutting an estimated $310M.

  • 1,128 institutional investors held Novartis (NVS) as of Q2 2020, down from 1,133 in Q1 2020.
  • Funds reported $20.7B of Novartis stock for Q2 2020, up 1.6% quarter-over-quarter.
  • 83 funds opened new Novartis positions in Q2 2020 and 78 closed out, a net change of +5 holders.
  • The largest Novartis buyer in Q2 2020 was Boston Partners, an estimated $290M added.
  • The largest Novartis seller in Q2 2020 was Dodge & Cox, an estimated $310M sold.

Based on aggregated 13F filings for Q2 2020.